.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,456,219

« Back to Dashboard

Claims for Patent: 7,456,219

Title:Polymorphs of suberoylanilide hydroxamic acid
Abstract:The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Inventor(s): Miller; Thomas A. (New York, NY), Richon; Victoria M. (New York, NY), Chiao; Judy H. (Berkeley Heights, NJ)
Assignee: Merck HDAC Research, LLC (Boston, MA)
Application Number:10/600,132
Patent Claims: 1. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, and 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instmment.

2. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, 43.3 degrees 2.theta., and lacking at least one peak at about <8.7, 10.0-10.2, 13.4-14.0, 15.0-15.2, 17.5-19.0, 20.1-20.3, 21,1-21.3, 22.0-22.22, 22.7-23.0, 25.0-25.5, 26.0-26.2, and 27.4-27.6 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instmment.

3. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I obtained by a purification process comprising the step of recrystallizing a crude preparation of SAHA from an organic solvent or a mixture of an organic solvent and water wherein the organic solvent is at least one of methanol, ethanol or isopropanol, the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0. and 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

4. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I obtained by a purification process comprising the step of recrystallizing a crude preparation of SAHA from an organic solvent or a mixture of an organic solvent and water wherein the organic solvent is at least one of methanol, ethanol or isopropanol, the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0. and 43.3 degrees 2.theta., and lacking at least one peak at about <8.7, 10.0-10.2, 13.4-14.0, 15.0-15.2, 17.5-19.0, 20.1-20.3, 21.1-21.3, 22.0-22.22, 22.7-23.0, 25.0-25.5, 26.0-26.2, and 27.4-27.6 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

5. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I obtained by a purification process comprising the step of recrystallizing a crude preparation of SAHA from an organic solvent or a mixture of an organic solvent and water, wherein the organic solvent is at least one of methanol, ethanol or isopropanol, the SAHA Form I is characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

6. An active ingredient consisting suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffiactiorh pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

7. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., and lacking peaks at about 13.4-14.0 and 22.7-23.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source.

8. The active ingredient according to any one of claims 1 2, 6 and 7, in plate shaped form.

9. The active ingredient according to claim 7, wherein the SAHA Form I is further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4 .+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

10. The active ingredient of any one of claims 1, 2, 3, 4, 5, 6 and 9, wherein the DSC measurement is performed by heating from 50.degree. C. at 10.degree. C. per minute to at least 30.degree. C. above the observed melting temperature.

11. The active ingredient of claim 10, wherein the DSC measurement is performed with Perkin Elmer standard aluminum DSC sample pans and covers, with a nitrogen gas purge rate at about 20 ml/min.

12. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I obtainable by a purification process comprising the step of recrystallizing a crude preparation SAHA from an organic solvent or a mixture of an organic solvent and water, wherein the organic solvent is at least one of methanol, ethanol or isopropanol, SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

13. An active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I obtainable by a purification process comprising the step of recrystallizing a crude prepartion of SAHA from an organic solvent or a mixture of an organic solvent and water, wherein the organic solvent is at least one of methanol, ethanol or isopronanol, the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., and lacking peaks at about 13.4-14.0 and 22.7-23.0 degrecs 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source.

14. The active ingredient according to claim 13, further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

15. The active ingredient of claim 12 or 14, wherein the DSC measurement is performed by heating from 50.degree. C. at 10.degree. C. per minute to at least 30.degree. C. above the observed melting temperature.

16. The active ingredient of claim 15, wherein the DSC measurement is performed with Perkin Elmer standard aluminum DSC sample pans and covers, with a nitrogen gas purge rate at about 20 ml/min.

17. The active ingredient of claim 13, wherein the crude preparation of SAHA is prepared by; a. reacting suberic acid with aniline to form suberanilic acid or a salt thereof having the structure: ##STR00057## b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00058## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture.

18. The active ingredient of claim 17, further comprising the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

19. The active ingredient according to claims 3, 4, 5, 12 to 14, 17 and 18 wherein organic solvent is methanol.

20. The active ingredient according to claims 8, 4, 5, 12 to 14, and 18, wherein said organic solvent is methanol. ethanol or isopropanol.

21. The active ingredient according to claims 3, 4, 5, 12 to 14, 17 and 18, wherein said purification process comprises the step of recrystallizing said crude SAHA from an organic solvent, wherein the organic solvent is at least one of methanol, ethanol or isopropanol.

22. The active ingredient according to claim 21, wherein said organic solvent is methanol.

23. The active ingredient according to claim 21, wherein said organic solvetn is methanol.

24. The active ingredient according to claim 21, wherein said organic solvent is ethanol.

25. The active ingredient according to any one of claims 3, 4, 5, 12 to 14, 17 and 18, wherein said purification process comprises the step of recrystallizing said crude SAHA from a mixture of an organic solvent and water, wherein the organic solvent is at least one of methanol, ethanol or isopropanol.

26. The active ingredient according to claim 25, wherein said organic solvent is ethanol.

27. The active ingredient according to claim 25, wherein said organic solvent is isopropanol.

28. The active ingredient according to claim 25, wherein said mixture of organic solvent to water comprises about 1-99% methanol, ethanol or isopropanol about 99-1% of water.

29. The active ingredient according to claim 25, wherein said mixture comprises about 15-85% methanol, ethanol or isopropanol and about 1-15% water.

30. The active ingredient according to claim 25, wherein said mixture comprises about 85% methanol, ethanol or isopropanol and about 15% water.

31. The active ingredient according to claim 25, wherein said mixture of organic solvent to water comprises about 1-99% ethanol and about 99-1% of water.

32. The active ingredient according to claim 25, wherein said mixture comprises about 15-85% ethanol and about 1-15% water.

33. The active ingredient according to claim 25, wherein said mixture comprises about 85% ethanol and about 15% water.

34. An active ingredient consisting a crystalline form of SAHA designated as Form I, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4. 17.5. 19.4. 20.0. 24.0 and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source, obtainable by a method comprising the step of recrystallizing a crude preparation of SAHA from a mixture of methanol and water.

35. The active ingredient according to claim 34, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

36. An active ingredient consisting of a crystalline form of SAHA designated as Form I, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at 9.0, 9.4, 17,5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, 43.3 degrees 2.theta., wherein the X-ray difraction is measured with a Copper X-ray source; obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid or a salt thereof having the structure: ##STR00059## b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00060## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

37. The activc ingredient according to claim 36, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

38. The active ingredient according to claim 36, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

39. An active ingredient consisting of a crystalline form of SAHA designated as Form I, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., and lacking peaks at about 13.4-14.0 and 22.7-23.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; obtainable by a method comprising the step of recrystallizing a crude preparation of SAHA from a mixture of methanol and water.

40. The active ingredient according to claim 39, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

41. An active ingredient consisting of a crystalline form of SAHA designated as Form I, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument; obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid or a salt thereof having the structure: ##STR00061## b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure; ##STR00062## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

42. The active ingredient according to claim 41, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

43. The active ingredient according to claim 41, wherein step (c) further comprises the steps of; (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc